Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT. · 2016

Read Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. by Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5106372.txt.

Introduction

Thomas R. Flint and seven co-authors traced how tumors blunt the immune system in Cell Metabolism in 2016. Their work centers on cachexia, the wasting that comes with cancer, and on interleukin-6, a signal that tumors release. They used mice with bowel tumors or pancreatic tumors to follow the chain of effects.

They found that tumor interleukin-6 weakens the liver's ability to make ketones, an backup fuel, when food is scarce. The shortfall triggers a surge in stress hormones, and those hormones shut down several immune attacks inside the tumor. Giving mice the stress hormone directly erased the benefit of an immunotherapy drug. The chain explains one way a tumor's effect on body metabolism can shield it from treatment.

Catalog record

CREATORFlint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5106372

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity By Thomas R Flint, Tobias Janowitz, Claire M Connell, Edward W Roberts, Alice E Denton, Anthony P Coll, Duncan I Jodrell, Douglas T Fearon Published in: Cell Metabolism DOI: 10.1016/j.cmet.2016.10.010 ABSTRACT Summary In patients with cancer, the wasting syndrome, cachexia, is associated with caloric deficiency. Here, we describe tumor-induced alterations of the host metabolic response to caloric deficiency that cause intratumoral immune suppression. In pre-cachectic mice with transplanted colorectal cancer or autochthonous pancreatic ductal adenocarcinoma (PDA), we find that IL-6 reduces the hepatic ketogenic potential through suppression of PPARalpha, the transcriptional master regulator of ketogenesis. When these mice are challenged with caloric deficiency, the resulting relative hypoketonemia triggers a marked rise in glucocorticoid levels. Multiple intratumoral immune pathways are suppressed by this hormonal stress response. Moreover, administering corticosterone to elevate plasma corticosterone to a level that is lower than that occurring in cachectic mice abolishes the response of mouse PDA to an immunotherapy that has advanced to clinical trials. Therefore, tumor-induced IL-6 impairs the ketogenic response to reduced caloric intake, resulting in a systemic metabolic stress response that blocks anti-cancer immunotherapy. Keywords: pancreatic cancer, cachexia, cancer immunology, hepatic metabolism, interleukin-6, PPARalpha, stress, ketogenesis, glucocorticoids, cancer immunotherapy INTRODUCTION Pancreatic ductal adenocarcinoma (PDA) is a leading cause of cancer death (Siegel et al., 2012). It is poorly responsive to available chemotherapies and unresponsive to checkpoint-targeted immunotherapies (Brahmer et al., 2012, Royal et al., 2010), and it predisposes patients to the lethal wasting syndrome, cachexia (Bachmann et al., 2013). Resistance to chemotherapy and immune evasion are topics of active research in PDA (Feig et al., 2013, Olive et al., 2009), but how PDA tumors alter host metabolism in cachexia and whether this affects the host’s immune interaction with the tumor are less studied questions. Cachexia, which is clinically defined by weight loss, represents a spectrum of disease. It initially arises as pre-cachexia, progresses to cachexia, and then progresses to refractory cachexia, a process that is driven by negative energy balance and abnormal metabolism (Fearon et al., 2011). The pathogenesis and progression of cachexia have been attributed in part to systemic elevations of pro-inflammatory cytokines (Fearon et al., 2012), but anti-cytokine therapies alone have not demonstrated clinical benefit. Cachexia-enhancing alterations such as increased catabolic signaling and increased uncoupling protein expression have also been described at the level of muscle and fat tissues, respectively (Kir et al., 2014, Petruzzelli et al., 2014, Zhou et al., 2010). It is not known, however, whether the normal host response to caloric deficiency, a central component of the syndrome (Fearon et al., 2011), is itself impaired in cachexia. Such an impairment might explain why macronutrient supplementation has failed to reverse cachexia in clinical trials (Tisdale, 2009). Altered macronutrient utilization must also be considered in the context of tumor biology and therapeutic resistance. Previous studies have highlighted the capacity of cancer cells to respond to alterations of the host metabolism (Kalaany and Sabatini, 2009, Park et al., 2010), but the stromal constituents of the tumor may also sense such alterations. One possibility, considering the sensitivity of intratumoral T cells to their local metabolic environment (Chang et al., 2015, Ho et al., 2015), as well as the marked effects of poor nutritional status on systemic immunity in other contexts (Keusch and Farthing, 1986), is a suppressive effect of cachexia on the T cell-mediated anti-tumor immune reaction. Such an effect could contribute to the failure of patients with PDA to respond to the current generation of T cell checkpoint targeted immunotherapies. In the present study, we have examined the interactions between cancer, systemic metabolism, and tumor immunology in mice using two cancer types that have been documented to predispose to cachexia, the transplanted C26 model of colorectal cancer (Tanaka et al., 1990) and the genetically engineered, autochthonous LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre/+ (KPC) model of PDA (Hingorani et al., 2005, Roberts et al., 2013). RESULTS Reprogrammed Hepatic Metabolism Is Evident in Pre-cachectic and Cachectic Mice C26 and PDA tumors cause cachexia, as defined by loss of body weight (Figures 1A, S1A, and S1B, available online), depletion of fat and muscle mass (Figures S1D and S1F), and elevated markers of muscle catabolism (Figures S1E and S1G). In both model systems, we observed that cachexia was associated with decreased food intake (Figures 1B and S1C). The cachexia-associated reduction in food intake was more pronounced in PDA-bearing relative to C26-bearing mice despite similar rates of weight loss, possibly reflecting differences in tumor size, tumor metabolic activity, and/or murine activity levels. Given the relevance of reduced food intake to cachexia (Fearon et al., 2011), we examined more closely the response to reduced food intake in the C26 and PDA systems. In order to avoid the confounding effects of differing food intake patterns that are well documented as a problem of pair-feeding experiments (Ellacott et al., 2010), we subjected weight-stable, pre-cachectic C26- and PDA-bearing mice, and the respective non-tumor-bearing littermate control mice, to 24 hr total food restriction (TFR) (Figures S1H and S1I). We measured endocrine markers and metabolites in all experimental groups (Figures 1C–1E and S2A–S2D). Cachectic and food-restricted pre-cachectic C26- and PDA-bearing mice had lower plasma glucose and ketone levels relative to food-restricted non-tumor-bearing controls (Figures 1C, 1D, and S2C). Metabolic stress, as measured by plasma levels of corticosterone, occurred in all food-restricted and cachectic mice (Figure 1E), but the highest corticosterone levels were observed in the food-restricted pre-cachectic groups, presumably in response to low levels of ketones and glucose (Figures 1C–1E, S2C, and S2D) (Amiel et al., 1991). Low levels of ketones and raised glucocorticoid levels during periods of continuous weight loss are not restricted to mouse models of cancer, for they were also present in patients with PDA and cachexia (Figures 1F, 1G, S1J, and S1K). [Figure: The Metabolic Response to Spontaneous or Imposed Food Restriction of Pre-cachectic Mice Bearing Transplantable C26 Tumors or Autochthonous PDA, and Translational Correlates in Patients with PDAWeight-stable mice with established C26 or PDA tumors that were yet to develop cachexia were termed pre-cachectic (C26/PreCx and PDA/PreCx, respectively). C26- and PDA-bearing mice were termed cachectic (C26/Cx and PDA/Cx, respectively) following >5% body weight loss from their peak weight.(A and B) Body weight (A) and cumulative food intake (B) were monitored in C26/PreCx, C26/Cx, PDA/PreCx, and PDA/Cx mice, and measurements were aligned to the time of sacrifice.(C–E) Terminal bleed plasma levels of (C) glucose and (D) ketones and tail bleed plasma levels of (E) corticosterone were assessed in littermates (LM), C26/PreCx and C26/Cx mice, and LM and C26/PreCx mice that had been subjected to 24 hr TFR (LM + TFR and C26/PreCx + TFR, respectively). Parallel assessments were performed in PDA-bearing mice, with LSL-Trp53R172H/+; Pdx-1-Cre/+ (PC) mice as the non-tumor-bearing controls.(F) Longitudinal pre-sampling weights for pre-cachectic and cachectic patients with pancreatic cancer are displayed.(G) Midday serum cortisol levels for both groups of patients are shown. The comparisons of data for LM, C26/PreCx, and C26/Cx mice, and for PC, PDA/PreCx, and PDA/Cx mice, were performed using one-way ANOVA with Tukey’s correction for post hoc testing. The LM + TFR versus C26/PreCx + TFR, PC + TFR versus PDA/PreCx + TFR, and pre-cachectic versus cachectic patient comparisons were each performed separately using two-tailed t

Read the complete text